Harmony Biosciences Q1 Revenue Up 17%, Reaffirms 2026 Guidance Over $1B

What happened

Harmony Biosciences reported Q1 2026 net revenue of $215.4 million for WAKIX, representing 17% year-over-year growth, which marked a deceleration from the strong 23% growth in 2024 and 29% in Q3 2025. The company attributed the slower start to typical first-quarter market access headwinds that were more pronounced this year, following three consecutive record quarters. Despite the softer Q1, management reaffirmed full-year 2026 net revenue guidance of over $1 billion, implying an acceleration in the remaining quarters. The company also reiterated its strategic priorities, including advancing the pitolisant franchise and pipeline programs. Overall, the Q1 results show continued commercial execution but with near-term noise from payor dynamics, while the long-term revenue trajectory remains consistent with the base-case scenario of 14-18% annual growth.

Implication

The Q1 report supports the base-case thesis that WAKIX can grow at a high-single to low-double-digit pace even with payor headwinds, but the 17% growth rate is below the 20%+ trajectory seen in recent quarters and may pressure near-term sentiment. The reaffirmed guidance of over $1 billion for 2026 implies needed acceleration to approximately 20% growth for the remaining quarters, which is achievable if access headwinds ease as typical. The core investment case remains intact: Harmony trades at ~11-12x trailing EPS with net cash and a durable WAKIX franchise, offering mid-teens annualized return potential over the next 6-18 months. However, investors must watch for any downward revision to guidance if Q2 also disappoints, which would trigger a reassessment of the thesis. The pipeline optionality from pitolisant HD and rare epilepsy assets remains a longer-term call option that adds to the asymmetrical risk/reward.

Thesis delta

No material shift in thesis. The Q1 2026 results are consistent with the base-case assumption of 14-18% annual WAKIX growth, albeit at the lower end due to seasonal headwinds. Confirmation of the $1B+ full-year guidance reinforces the view that growth will re-accelerate, and the current valuation still offers an attractive entry near $36. However, the slightly slower start increases the importance of upcoming quarters to validate the trajectory; if growth disappoints, the stock could re-rate lower.